Insitro and Bristol Myers Squibb Partner to Advance AI-Driven Discovery of ALS Treatments
Wednesday, October 15, 2025
insitro has announced an extension of its partnership with Bristol Myers Squibb to advance the discovery of novel treatments for amyotrophic lateral sclerosis (ALS).
The one-year extension will utilise insitro’s ChemML™ platform to design potential medicines targeting a new ALS-related biological pathway identified during the initial research phase. The agreement may provide up to USD 20 million in new funding, with the collaboration’s total potential value exceeding USD 2 billion, including discovery, development, regulatory, and commercial milestone payments, along with royalties.
The ChemML™ platform is designed to accelerate small molecule discovery and optimisation through artificial intelligence and machine learning. It integrates multiple digital and laboratory-based capabilities, enabling rapid data generation and predictive modelling. Key features of the platform include:
- Large-scale data generation: Quantitative Adaptive Libraries (QALs) capable of producing hundreds of millions of drug-target interaction data points to enhance machine learning models.
- Predictive pharmacological modelling: Advanced algorithms predicting pharmacokinetic and toxicity properties using extensive datasets from industry collaborations.
- AI-guided design process: An iterative cycle combining computational predictions and experimental data to streamline synthesis and testing.
- High-performance computing: Access to a large GPU cluster to support complex modelling and simulation tasks.
Through this collaboration, several promising ALS drug targets have been identified, supported by evidence of motor neuron survival and reversal of disease-related cellular markers. These findings offer opportunities to develop new small molecule therapies addressing challenging biological mechanisms.
ALS is a progressive neurodegenerative disorder that causes the loss of motor neurons, leading to muscle weakness, respiratory failure, and eventual death, typically within three to five years after diagnosis. Since most ALS cases occur sporadically, the research collaboration focuses on identifying shared disease mechanisms that could lead to treatments benefiting both familial and sporadic forms.
insitro and Bristol Myers Squibb continue to work together to translate scientific discoveries into effective therapies for individuals affected by this debilitating condition.
Source: insitro.com
